
CEOs globally brace for tariff turmoil with a new game plan
In interviews with CNBC this earnings season, CEOs across industries — from aluminum and aerospace to chocolate, banking, telecoms, and energy — sent a clear message: tariffs are no longer just a political tactic.
As trade rules grow more uncertain and tariffs resurface in policy discussions, business leaders say they're rethinking everything from where factories are located to how products are priced. The old 'just in time' model is giving way to something more cautious: make goods closer to the buyer, ask for exemptions where possible, and stay alert to shifting consumer habits.
This earnings season has been marked by currency swings, inflation, and political uncertainty. And in that environment, tariffs are no longer background noise. They're front and center in how companies are managing risk. For many in the C-suite, the threat isn't just about short-term costs — it's about staying competitive for the long haul.
Build local, think political
'We are concerned about the competitiveness of aluminum compared to other materials,' Hydro Chief Financial Officer Trond Olaf Christophersen told CNBC earlier this week. The company is already passing U.S. tariff costs onto customers. But the deeper worry is how, 'some customers in packaging are already testing steel and plastic alternatives. That's the long game we're watching.'
For Christophersen, it's not just a quarterly issue — it's a warning sign. And Hydro's concern reflects a broader shift: tariffs are speeding up lasting changes in how companies do business.
One of the most common responses is moving production closer to customers. Ericsson CEO Börje Ekholm told CNBC the company's North American factory, opened in 2020, was a forward-looking move. 'We've had that 'Made in America' stamp for some time,' he said. The facility now helps protect the company from shifting global politics.
Volvo Cars CEO Håkan Samuelsson is also focused on the U.S. 'We want to fill our factory in South Carolina,' he told CNBC, noting that the company is breaking operations into more independent regions so local teams can respond quickly to new trade policies.
Pharma giant AstraZeneca is also pivoting its footprint, rapidly shifting manufacturing to the U.S. and planning a $50 billion investment in local operations. 'We have lots of reasons to be here,' CEO Pascal Soriot said on the company's earnings call.
For others, localization is as much about sovereignty as it is about logistics. 'We are building data centers for American hyperscalers in Europe, but also for Europeans in the U.S. It's a conscious decoupling,' Skanska CEO Anders Danielsson told CNBC. 'Sovereign tech is a real priority.'
Not every company can shift where things are made. Some are relying on diplomacy. Rolls-Royce CFO Helen McCabe told CNBC the aerospace firm worked with U.K. and U.S. governments to win exemptions for key parts. 'It's not just about tariffs,' she said. 'It's about aligning our industrial footprint to minimize any friction.'
That kind of behind-the-scenes outreach points to a bigger change: trade policy has become a key part of business planning. More companies are factoring in government relations and political risk when making decisions.
Price hikes, policy risk and volatility
Even the most proactive companies can't prepare for everything. Some are eating the higher costs. Others are raising prices — carefully.
Lindt & Sprüngli, the premium chocolate maker, raised prices by 15.8% this year to offset soaring cocoa costs, driven partly by export restrictions in West Africa. 'We saw only a 4.6% decline in volume mix,' CEO Adalbert Lechner told CNBC. But he admitted that U.S. consumers are becoming more price-sensitive.
Givaudan CEO Gilles Andrier shared a similar view. 'Some of our natural ingredients come from Africa and Latin America,' he told CNBC. 'So we're exposed to some tariffs there.' Even companies with local factories can't avoid all trade impacts when raw materials come from abroad.
For companies tied to commodities, the trade duties are just one piece of a bigger puzzle: unpredictability.
'The tricky thing was, it was non-fundamentals-based volatility,' Shell CEO Wael Sawan told CNBC, describing recent swings in the oil market. 'This wasn't a change to physical commodity flows. This was really sort of paper-induced volatility.' That, he said, makes it harder to plan investments or manage price risk.
Even in banking, where the direct impact of tariffs might seem small, the consequences are showing up.
'When you price risk now, you can't just look at credit or liquidity. You have to model policy unpredictability,' UniCredit CEO Andrea Orcel told CNBC. That includes trade tensions, regulatory surprises, and election-related gridlock.
This quarter makes one thing clear: policy is now a core business risk, not background noise. With elections ahead and industrial policy shifting, companies are localizing, diversifying, lobbying, and repricing faster than ever.
Tariffs aren't just a cost — they're reshaping industries. When customers trade aluminum for steel or chocolate for cheaper treats, the threat isn't just margins. It's market share.
So yes, leaders are building closer to home, pricing smarter, negotiating harder as they scramble to stay ahead of the next curveball.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
25 minutes ago
- The Hill
Proposed rule bans nearly all abortions at VA hospitals
The VA said in the proposal that it is reversing a 2022 rule that for the first time allowed the department to provide abortions in limited circumstances to pregnant veterans and their eligible family members, even in states that banned abortion after the Supreme Court overturned Roe v. Wade. Between 1999 and 2022, the VA excluded almost all abortions and abortion counseling for veterans and their families from their medical benefits package. By reversing the rule, officials are seeking to ensure taxpayer dollars are not used to terminate pregnancies, according to a filing released Friday. They also called the Biden administration's decision to implement the interim rule 'inappropriate' and 'legally questionable.' A final rule could come as soon as the public comment period on the measure closes on Sept. 3. Reproductive rights groups said the move robbed service members of the ability to control their bodies and their futures. 'Since taking office, the Trump administration has repeatedly attacked service members, veterans, and their families' access to basic reproductive care, including gender-affirming care,' Alexis McGill Johnson, president and CEO of Planned Parenthood Federation of America, said, referring to the VA's decision in March to stop providing transgender veterans with hormone therapy. 'Taking away access to health care shows us that the Trump administration will always put politics and retribution over people's lives.' Anti-abortion groups, meanwhile, applauded the Trump administration's decision, calling it a 'major win' for the movement. 'Instead of prioritizing the real and urgent needs of our veterans, the Biden-Harris Administration turned VA hospitals into abortion centers – violating longstanding law and betraying the will of the American people who strongly oppose forced taxpayer-funded abortions,' the anti-abortion group Susan B. Anthony Pro-Life America said in a statement. 'Thankfully, this injustice is now corrected.'


CNBC
26 minutes ago
- CNBC
Shake Shack CEO says 'productivity' helps mitigate inflated beef costs
Shake Shack CEO Rob Lynch reviewed his company's most recent quarter in a Monday interview with CNBC's Jim Cramer, and he described how the burger chain manages to mitigate the inflated cost of ingredients like beef without steep price hikes. "We've built so much productivity over the last year, our operating margins have gone from right around 20 up to 24%, almost 24% last quarter," he said. "We're right now working within our supply chain to find a lot more productivity, so we're able to mitigate that inflation with all the productivity." Even as Shake Shack beat revenue and earnings estimates when it reported last week, shares declined as investors worried about a lower-than-expected same-store sales figure. The stock is currently down a little over 11% year-to-date. According to Lynch, Shake Shack no longer depends on pricing to drive growth and now sees traffic as a significant driver of "healthy, sustainable growth." He said Shake Shack is "never going to be the lowest price point product out there," as its products cost more to make. Lynch said the company is looking at other ways to provide customers with value, such as a $1 drink promotion on its app. He also mentioned newer offerings, like alcoholic beverages — "boozy shakes, classic cocktails, full bar" — at certain locations. Lynch maintained that Shake Shack has pricing power if inflation skyrockets. "I mean, we still have pricing power, if we choose, if we need to, if there's enough inflation," he said. "So pricing will always be a part of the model, but it's, we're not dependent upon it like we used to be." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest
Yahoo
42 minutes ago
- Yahoo
Why Curaleaf Stock Popped by 15% on Monday
Key Points Good news benefiting the cannabis industry was beneficial for the company too. There were pot-positive developments on both the medical and political fronts. 10 stocks we like better than Curaleaf › Pardon the use of the adjective, but it was obvious on Monday that the market has high hopes for cannabis company Curaleaf (OTC: CURLF). Investors piled into the stock after some positive news developments affecting its industry hit the headlines. By the time the smoke had cleared, Curaleaf was left standing with a more than 15% gain in its stock price that day. This obliterated the 1.4% advance of the S&P 500 index. Drug of choice The first news item producing that buzz was research published by the influential American Medical Association (AMA). In its Journal of the American Medical Association, the AMA detailed research from a survey that evaluated a clutch of drugs for how they affected eating disorders. Of the numerous drugs tested, the Journal noted, cannabis and psychedelic compounds were the highest-rated for alleviating symptoms of eating disorders. On top of that, marijuana and the psychedelics LSD and psilocybin also performed well in terms of overall mental health. These contrasted with the generally weak showing of nicotine and alcohol, which the Journal said were frequently ranked by the respondents as being the most harmful substances. Marijuana is legally sold as a medicine to qualifying patients in most U.S. states. If the drug can indeed treat eating disorders, this could dramatically enhance its appeal as a medical drug. Pot lobbying Another item of interest was Federal Election Commission (FEC) filings cited by several media outlets revealing that a pot industry-supported political action committee (PAC) made a meaty donation to President Trump's MAGA Inc. This is a so-called "super PAC" entitled to raise unlimited amounts of money to support political figures. The American Rights and Reform PAC, fueled by donations from marijuana companies, has donated $1 million to MAGA Inc. Although that's relatively small given the over $177 million the latter absorbed in the first six months of the year, this does indicate that the weed industry is actively lobbying influential people in U.S. politics. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Popped by 15% on Monday was originally published by The Motley Fool Sign in to access your portfolio